CorMedix (CRMD) – From single-asset grind to commercial anti-infective platform 

1. Where CRMD stands after 2025 – the company is not what it used to be

For a long time CorMedix was essentially a single-asset story: get DefenCath approved, fix manufacturing, survive cash crunch after cash crunch and hope the U.S. dialysis market would eventually show up. Your earlier Merlintrader pieces captured that phase very well: constant delays, regulatory setbacks, capital raises and a community of investors stuck between conviction and fatigue.

The full-year 2025 numbers mark a clean structural break with that history. On paper, CRMD is now a commercial anti-infective platform with more than US$300M of annual revenue, two business engines (DefenCath and the Melinta portfolio) and a very different balance sheet. Total revenues in 2025 reached US$311.7M, up from just US$7.0M in 2024. Of that, an impressive US$258.8M came from DefenCath net product revenue and US$52.9M from Melinta products consolidated after the February 2025 closing of the deal.:contentReference[oaicite:1]{index=1}

The good news is that CRMD is finally playing in the revenue league it always promised. The less comfortable part is that this transformation comes with a much more complex P&L, much higher operating expenses, material intangible assets and a capital structure that investors need to actually read, not just gloss over. The deep dive here is exactly about that: understanding what is “real, repeatable operating performance” and what is accounting optics.

2. What the 2025 numbers really say – big revenue, bigger accounting noise

At the top line, the story is straightforward: DefenCath and Melinta together created a completely different revenue base. Total revenues jumped to US$311.7M from US$7.0M in 2024. The 2025 mix is heavily skewed to DefenCath (US$258.8M) with Melinta contributing US$52.9M in less than a full year of consolidation. In 2024, DefenCath only generated US$5.6M and other revenue US$1.4M – essentially the last year of “old CRMD”.:contentReference[oaicite:2]{index=2}

Operating expenses also changed scale. Total operating expenses in 2025 were US$125.6M, double the US$62.6M reported in 2024, reflecting a full commercial infrastructure, integration costs and higher R&D to support the broader portfolio. Within that, R&D and SG&A both increased meaningfully, and there is now a recurring amortisation charge on Melinta intangibles. This is no longer the lean, development-stage entity that could cut costs quickly if needed – there is a real fixed-cost base to feed.:contentReference[oaicite:3]{index=3}

The headline GAAP net income of US$163.0M (US$2.04 per diluted share) for 2025 looks spectacular next to the US$17.9M net loss in 2024 – but it is almost entirely driven by non-cash items. “Other income” swung from a US$1.7M expense in 2024 to US$195.0M of income in 2025, mainly due to a US$247.7M bargain-purchase gain from the Melinta acquisition, partially offset by a US$52.9M non-cash impairment of intangible assets and fair-value adjustments.:contentReference[oaicite:4]{index=4}

In simple terms: the core business is not throwing off US$163M of free cash every year. The underlying economic picture is closer to “solid adjusted EBITDA, but still a business that has to prove durability of its revenue and margins”. Full-year 2025 Adjusted EBITDA was US$184.7M versus US$17.5M in 2024, and Q4 2025 Adjusted EBITDA reached US$77.2M, up from US$15.3M a year earlier – a real inflection at the operating level, but one that is very sensitive to how DefenCath and the Melinta assets perform in 2026–2027.:contentReference[oaicite:5]{index=5}

3. Balance sheet, cash and the new scale of the company

The Melinta acquisition and DefenCath ramp reshaped the balance sheet. As of December 31, 2025, CorMedix reported US$148.5M in cash, cash equivalents and short-term investments, plus US$16.5M in restricted cash. That compares with US$148.1M of cash and investments and just US$0.3M of restricted cash a year earlier. At first glance, cash looks “flat” – but the company now sits on a much larger asset and liability base.:contentReference[oaicite:6]{index=6}

Total assets jumped to US$826.1M from US$231.0M in 2024. Total liabilities increased to US$420.8M (vs US$74.9M), and stockholders’ equity rose to US$405.3M from US$156.1M. This reflects the consolidation of Melinta’s operations, intangibles (brands, IP, relationships) and the associated obligations – a very different capital structure than the “small biotech plus one product” setup investors were used to.:contentReference[oaicite:7]{index=7}

The positive angle is that CRMD now controls a broad anti-infective portfolio and a meaningful revenue engine. The uncomfortable angle is that there is less room for error. Servicing the combined platform requires sustained commercial performance from both DefenCath and Melinta’s hospital products; any stumble in pricing, reimbursement or volume will hit not only the P&L but the perceived safety of the balance sheet.

4. DefenCath – finally a real business, but with a lot still to prove

DefenCath has always been the emotional core of the CRMD story: prevent catheter-related bloodstream infections in hemodialysis patients, save lives, reduce hospitalisations and – if the economics work – build a durable, high-margin hospital franchise. For years this remained theoretical. 2025 is the first time we can look at DefenCath and say: there is now a serious commercial footprint.

Net product revenue from DefenCath reached US$258.8M in 2025, up from just US$5.6M in 2024. That is not a linear ramp; it is the combination of launch progression, label, channel expansion and higher adoption by dialysis providers once supply and logistics became more predictable. On a quarterly basis, Q4 2025 contributed a large chunk of the annual figure, underlining that the product exited the year with a very different run-rate than it started with.:contentReference[oaicite:8]{index=8}

The critical questions for 2026–2027 are less about “does DefenCath work?” – the clinical and practical case is relatively clear – and more about:

• Depth of penetration – how close does CRMD get to being a standard of care in the relevant dialysis population, and how fast?
• Pricing & reimbursement – can the company defend its economics in a system that relentlessly pressures hospital budgets?
• Label and geography work – how far can the DefenCath concept be extended (additional indications, regions) without overstretching resources?

From a numbers perspective, DefenCath is already the main pillar of the revenue line. From a risk perspective, it is also the main point of failure: if growth stalls or reimbursement comes under pressure, the entire “platform” narrative loses its anchor.

5. Melinta – second engine with its own opportunities and headaches

The Melinta acquisition brought a portfolio of branded hospital anti-infectives into CRMD: drugs used in severe infections, post-surgical settings and complicated patients. In 2025, Melinta contributed US$52.9M in net product revenue to reported figures (partial-year consolidation) but on a pro forma basis, the combination of DefenCath and Melinta would have generated US$401.3M of total revenues in 2025.:contentReference[oaicite:9]{index=9}

That pro forma view is important: it tells investors that Melinta is not a tiny bolt-on but a substantial revenue stream in its own right. At the same time, it comes with a very different risk pattern than DefenCath. These are mature hospital brands, exposed to generic competition, formulary dynamics and the grinding reality of hospital procurement.

Strategically, the Melinta assets do three things for CRMD:

• Provide a baseline of hospital revenue that is less binary than classic “one-shot” biotech launches.
• Give CRMD a broader commercial infrastructure – sales force, contracting desks, relationships – that can also support DefenCath.
• Add complexity: more brands to manage, more SKUs, more negotiations, more potential for execution mistakes.

In the 2025 numbers, you can already see the double edge. Melinta brings real Adjusted EBITDA, but also pushes up SG&A, amortisation and the size of intangible assets that can later be impaired if performance disappoints.

6. Ownership, institutions and sentiment – who is actually on this ride?

Ownership data show that CRMD is no longer a pure retail battleground. Public filings indicate that over 300 institutional investors now hold more than 40 million shares in aggregate – a mix of healthcare specialists, small-cap funds and passive strategies that track indices where CRMD appears.

That said, the stock still trades with a strong retail component. The long history of “DefenCath waiting room”, the emotional rollercoaster of past CRLs and capital raises, and the sharp post-news moves keep CRMD firmly on the radar of active traders. You can see this in the way the stock often over-reacts both to good and bad news, and in the tone of discussion around each new milestone.

Qualitatively, the current sentiment split looks like this:

• Long-time believers – investors who rode the pre-revenue years and see 2025 as the long-delayed validation of their thesis. They tend to focus on DefenCath scale, hospital need and the idea that the market still does not reflect the new revenue base.
• Skeptical fundamentalists – people who accept that revenues are now big but worry about the quality of earnings, the size of non-cash gains, future competition and the complexity of running a mini-group structure.
• Short-term traders – participants who treat CRMD as a high-beta trading instrument around earnings, guidance, reimbursement headlines and general biotech risk-on/off moves, without necessarily committing to a long-term view.

As always, comments and “hot takes” on social platforms like Reddit, Stocktwits and X come from non-professional traders and should be read as sentiment, not research. They matter because they influence volatility and liquidity, not because they replace SEC filings or official guidance.

7. Bull vs bear case – what has really changed after FY 2025?

7.1 Bull case – a discounted anti-infective platform with leverage to execution

The constructive view starts from a simple observation: CRMD is now generating over US$300M of annual revenue with a drug (DefenCath) that addresses a painful problem in a high-value setting, plus a portfolio of hospital anti-infectives that already have labels, supply chains and customers. On that base, a ~US$550M market cap looks low compared with many biotech names that still have no approved products.

In that bull framework:

• DefenCath can continue to grow volumes and maintain pricing in U.S. dialysis, potentially expanding to additional use-cases or regions.
• Melinta’s portfolio provides a relatively stable revenue floor, even if individual brands face pressure.
• The balance sheet, with over US$160M of cash and restricted cash and more than US$400M of equity, gives management room to navigate bumps without emergency financing.
• If execution is decent, the stock could re-rate towards more “normal” revenue and EBITDA multiples for commercial anti-infective franchises.

7.2 Bear case – messy accounting, high opex and a history that the market has not forgotten

The cautious or negative view focuses on the parts of the story that are less pretty. First, the impressive GAAP profit in 2025 is strongly driven by a one-off bargain-purchase gain from Melinta, alongside other non-cash items. Strip those out, and what remains is an organisation with a high fixed-cost base, heavy amortisation and a lot of execution risk still ahead.

Second, Melinta’s brands live in a competitive, price-sensitive environment. Generics, formulary decisions and hospital budget cycles can put pressure on volumes and pricing in ways that are not fully visible in a single year’s numbers. DefenCath itself, while attractive on paper, still has to prove how sustainable its growth is over multiple years of real-world usage.

Third, CRMD’s history – multiple delays, prior capital raises, investor fatigue – means that the market will likely demand several clean quarters of delivery before assigning a rich multiple. Any stumble on guidance, reimbursement or execution can quickly bring back old doubts, with the stock behaving more like a trading vehicle than a steady compounder.

8. What to watch in 2026–2027 – concrete questions, not abstract narratives

After the 2025 step change, the CRMD story is less about “will they ever get to market?” and more about a handful of very concrete questions:

• DefenCath trajectory – do quarterly revenues keep moving up from the 2025 exit run-rate, or do we see plateaus and volatility?
• Melinta stability – can the hospital portfolio hold or modestly grow revenues in the face of competitive and pricing pressures?
• Cost discipline – does management keep operating expenses under control relative to revenue growth, or do we see “empire building”?
• Cash-flow profile – how quickly do Adjusted EBITDA and operating cash flow converge towards a more traditional, self-funding profile?
• Capital allocation – if the company generates real cash, does it reinvest sensibly (R&D, lifecycle management) or drift into unfocused M&A?

For existing holders, the key is whether the painful waiting years are finally being compensated by a business that now just needs to execute, or whether 2025 will look, in hindsight, like the peak of a one-off accounting and acquisition wave. For new investors, the question is simpler: at current prices, is the mix of upside and downside skewed enough to justify the volatility?